Bevacizumab - Biosimilars Insight, 2024
Introduction
Bevacizumab, a monoclonal antibody, has transformed the landscape of oncology since its approval. Known for its efficacy in treating various cancers, including colorectal, lung, and renal, it works by targeting vascular endothelial growth factor (VEGF). This article provides an overview of Bevacizumab and its biosimilars, focusing on...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian